Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $115.48 | 6 | 58.7% |
| Education | $81.24 | 2 | 41.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Insmed, Inc. | $81.24 | 2 | $0 (2022) |
| Allergan Inc. | $61.91 | 3 | $0 (2018) |
| AbbVie Inc. | $53.57 | 3 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $39.22 | 2 | AbbVie Inc. ($39.22) |
| 2022 | $65.00 | 1 | Insmed, Inc. ($65.00) |
| 2021 | $14.35 | 1 | AbbVie Inc. ($14.35) |
| 2020 | $16.24 | 1 | Insmed, Inc. ($16.24) |
| 2018 | $37.83 | 2 | Allergan Inc. ($37.83) |
| 2017 | $24.08 | 1 | Allergan Inc. ($24.08) |
All Payment Transactions
8 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/08/2023 | AbbVie Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $18.52 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/30/2023 | AbbVie Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $20.70 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/13/2022 | Insmed, Inc. | Arikayce (Drug) | Education | In-kind items and services | $65.00 | General |
| Category: Respiratory | ||||||
| 08/28/2021 | AbbVie Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $14.35 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/03/2020 | Insmed, Inc. | — | Education | In-kind items and services | $16.24 | General |
| 03/19/2018 | Allergan Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $23.08 | General |
| Category: ANTI-INFECTIVE | ||||||
| 01/09/2018 | Allergan Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $14.75 | General |
| Category: ANTI-INFECTIVE | ||||||
| 06/21/2017 | Allergan Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $24.08 | General |
| Category: ANTI-INFECTIVE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 28 | 45 | $11,790 | $3,308 |
| 2022 | 5 | 344 | 541 | $149,348 | $42,158 |
| 2021 | 10 | 979 | 13,920 | $677,013 | $270,467 |
| 2020 | 11 | 1,063 | 9,924 | $664,836 | $231,359 |
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 17 | 34 | $6,290 | $2,011 | 32.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 11 | 11 | $5,500 | $1,297 | 23.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 118 | 125 | $62,500 | $17,354 | 27.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 133 | 277 | $51,245 | $14,794 | 28.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 61 | 103 | $27,089 | $7,771 | 28.7% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 18 | 18 | $6,246 | $1,715 | 27.5% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 14 | 18 | $2,268 | $523.21 | 23.1% |
| J0875 | Injection, dalbavancin, 5 mg | Office | 2021 | 27 | 12,400 | $285,200 | $153,476 | 53.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 261 | 281 | $121,111 | $39,996 | 33.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 289 | 555 | $102,675 | $29,415 | 28.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 194 | 350 | $92,050 | $27,226 | 29.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 68 | 72 | $24,984 | $7,207 | 28.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2021 | 29 | 90 | $21,420 | $4,881 | 22.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 22 | 44 | $10,428 | $3,062 | 29.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 31 | 65 | $10,595 | $2,999 | 28.3% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 40 | 45 | $5,670 | $1,317 | 23.2% |
| 99449 | Telephone or internet assessment and management service provided by consultative physician, 31 minutes or more of medical consultative discussion and review | Facility | 2021 | 18 | 18 | $2,880 | $888.00 | 30.8% |
| J0875 | Injection, dalbavancin, 5 mg | Office | 2020 | 20 | 8,100 | $186,300 | $93,851 | 50.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 265 | 286 | $123,266 | $43,093 | 35.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 331 | 653 | $120,805 | $36,416 | 30.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 175 | 323 | $84,949 | $25,852 | 30.4% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2020 | 27 | 170 | $40,460 | $9,004 | 22.3% |
| 99183 | Management and supervision of oxygen chamber therapy per session | Facility | 2020 | 14 | 86 | $50,052 | $7,191 | 14.4% |
| 99449 | Telephone or internet assessment and management service provided by consultative physician, 31 minutes or more of medical consultative discussion and review | Facility | 2020 | 96 | 99 | $15,840 | $5,144 | 32.5% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 44 | 49 | $17,003 | $4,990 | 29.3% |
About Dr. Thomas Taft, MD
Dr. Thomas Taft, MD is a Infectious Disease healthcare provider based in Brookfield, Wisconsin. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1851341994.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Taft, MD has received a total of $196.72 in payments from pharmaceutical and medical device companies, with $39.22 received in 2023. These payments were reported across 8 transactions from 3 companies. The most common payment nature is "Food and Beverage" ($115.48).
As a Medicare-enrolled provider, Taft has provided services to 2,414 Medicare beneficiaries, totaling 24,430 services with total Medicare billing of $547,292. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Practice Information
- Specialty Infectious Disease
- Location Brookfield, WI
- Active Since 05/11/2006
- Last Updated 01/07/2025
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1851341994
Products in Payments
- DALVANCE (Drug) $96.96
- Arikayce (Drug) $65.00
- TEFLARO (Drug) $18.52
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.